🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Utility of ctDNA in cHL from SWOG Cancer Research Network S1826: 1. Clearance at C3D1 & EOT associated w PFS 2. MTB trajectory at C3D1 identified high vs. low risk groups Excellent questions from Ash Alizadeh, MD/PhD 🇺🇸 regarding PPV, NPV in Nivo-AVD & BV-AVD arms & assay performance International Conference on Malignant Lymphoma #18ICML #lymsm

BR for anti-MAG neuropathy International Conference on Malignant Lymphoma| How does the efficacy and toxicity compare with R monotherapy? BR for which group of patients? #18ICML #lymsm

DIRECT Study: ctDNA in DLBCL International Conference on Malignant Lymphoma #18ICML #lymsm

inMIND ph3 Tafa+R2 for r/r FL International Conference on Malignant Lymphoma 57% ⬇️ in risk of progression, relapse, or death OS immature Fixed duration✅ U.S. FDA approved ✅ Kudos to Laurie Sehn at the investigators #18ICML #lymsm

Philippe Giguère BC Cancer Ash Alizadeh, MD/PhD 🇺🇸 Adam Raymakers David Russler-Germain, MD/PhD International Conference on Malignant Lymphoma Here’s an updated version of our table - in addition the POLARIX Asian extension cohort found the same thing, plus our observational cohort of >700 patients presented at ASH. So 11/12 studies (7/8 trials, POLARGO being the first exception) show the same trend #18ICML

Highlights from Dr. Alizadeh’s talk on resistance to T-cell redirecting therapies: - Tumor escape mechanisms - Antigen loss & microenvironmental factors - Clinical implications & next-gen strategies #18ICML #ICML2025

Ajay Major, MD, MBA For our friends and our colleagues, especially those in community oncology, if you had the proverbial gun to your head, and you really had to chose between either MRD at End of Rx vs any or all of these various genetic classifiers to define 5/6/7/8 DLBCL subtypes as proposed by

#18ICML Big Debate: CNS prophy in DLBCL - Dr. Ferreri argues CNS relapse with v poor survival & suboptimal salvage options - He argues HD-MTX benefit outweighs toxicity, especially for high-risk EN sites - in his center experience, no CNS relapses with HD-MTX #lymsm 1/

🚨🚨We are pleased to publish the next output via the HoLISTIC consortium (Hodgkin Lymphoma International STudy for Individual Care: hodgkinconsortium.com): The E-HIPI (Early-Stage Hodgkin International Prognostic Index) prediction model for early-stage Hodgkin lymphoma. 1/9🧵

What is the optimal strategy for initial CLL/SLL Rx? Short-term BCL2 targeting OR Continuous BTK inhibition International Conference on Malignant Lymphoma #18ICML #lymsm

Pola-R-CHP the new SOC for ALL DLBCL? Soni Smith MD YES vs. Greg NO Pola-R-CHP, RCHOP Some need Pola-R-CHP Some don't have access to Pola Some will be fine with RCHOP International Conference on Malignant Lymphoma #18ICML #lymsm

What is the the impact of response (CR vs. PR vs. PD) after HD MTX based induction on outcomes after ASCT for untreated PCNSL? 🚫difference in PFS between CR and PR prior to ASCT, 2-yr PFS 76% 🚫 difference in OS between CR and PR prior to ASCT Poor outcome with PD, 2-yr PFS

Zanubrutinib monotherapy for r/r PCNSL ORR at 8wks 55% Interesting PK🤔 Eagerly await results from combo regimen International Conference on Malignant Lymphoma #18ICML #lymsm

CONGRESS | #18ICML | PRESENTATION Lakshmi Nayak, Dana-Farber shares results from the phase II PROSPECT trial of tirabrutinib in patients with R/R PCNSL (N = 48). With an ORR of 67%, a CR/CRu rate of 44%, a median DOR of 9.3 months, and a manageable safety profile, these results

Zamto-cel Tandem CD20-19 CAR T in r/r CNSL vein-to-vein time 14d👍 ORR 86% CRR 64% 🚫 grade ≥3 CRS 🚫 grade ≥3 ICANS Delayed response compared to DLBCL cohort 🚫 pts with radiographic LMD although some with CSF+ Comparable safety & efficacy data as DLBCL cohort w/o CNS

CONGRESS | #18ICML | PRESENTATION Shu Cheng, Shanghai Institute of Hematology at Ruijin Hospital Shanghai Jiao Tong University shares results from a phase II trial of tazemetostat plus amdizalisib in patients with R/R PTCL (N = 29). Tazemetostat plus amdizalisib demonstrated favorable responses in

Impressive results with Linperlisib+CHOP as 1L for PTCL 🔹CR 54% 🔹ORR 68% awaiting survival data and longer follow up International Conference on Malignant Lymphoma #18ICML #lymsm